A cluster-randomized trial conducted in Kwale, Kenya tested monthly ivermectin administration in children over a three-month period to evaluate its impact on malaria transmission. The study demonstrated a 26% reduction in new infections compared to control groups treated with albendazole. Published in The New England Journal of Medicine, the trial suggests ivermectin as a promising vector control additive to overcome challenges posed by insecticide resistance and outdoor mosquito biting, supporting integration into malaria control programs for high-burden regions.